HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $12.
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $12.